28 November 2023 - - Daiichi Sankyo today announced that Daichirona for intramuscular injection (DS-5670) for booster vaccination has been approved in Japan as an Omicron XBB.1.5-adapted monovalent mRNA vaccine against COVID-19.
Daiichi Sankyo had submitted a supplemental new drug application to Japan’s Ministry of Health, Labour and Welfare for manufacturing and marketing approval of the Omicron XBB.1.5 adapted monovalent mRNA vaccine in September 2023.